Lanifibranor Active Not Recruiting Phase 2 Trials for Type 2 Diabetes Mellitus / Non-Alcoholic Steatohepatitis (NASH) Treatment

Indications	Status	Purpose	Phase
DBCOND0029752 (Type 2 Diabetes Mellitus) DBCOND0040278 (Non-Alcoholic Steatohepatitis (NASH))	Active Not Recruiting	Treatment	2

clinicaltrials.gov Identifier	Title	Drugs
NCT05232071	Placebo-controlled, Proof-of-concept Study to Evaluate the Safety and Efficacy of Lanifibranor Alone and in Combination With SGLT2 Inhibitor EmpaGliflozin in patiEnts With NASH and Type 2 Diabetes Mellitus	Empagliflozin (DB09038) Lanifibranor (DB14801)